This still puts Merck near the top of the venerable firm's holdings in the pharma space, by dollar weighting. Here is the morning's full text SEC filing -- on Schedule 13G.
This is reduced from the zenith -- at 7 per cent -- breached last year, this time. But as I say, still respectable. Very. . . respectable:
Here is last year's item on this -- for perspective. Off to enjoy a foggy, London style Monday morning.
No comments:
Post a Comment